05-09-05

12

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

	Application Number	10/664,513
	Filing Date	September 16, 2003
	First Named Inventor	Marc K. HELLERSTEIN
	Art Unit	1645
	Examiner Name	Not Yet Assigned _
_	Attorney Docket Number	416272003700

•	ENCLO	SURES (Check all	that appl	y)	
Fee Transmittal Form		Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply	'	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final	1 1 1	Petition to Convert to a Provisional Application		Proprietary Information	
Affidavits/declara		Power of Attorney, Revocation Change of Correspondence		Status Letter	
Extension of Time Requ	uest	Terminal Disclaimer		Other Enclosure(s) (please Identify below):	
Express Abandonment	Request	Request for Refund		 PTO/SB/08a/b (8 pages) 97 Cited References 	
x Information Disclosure (Supplemental, 3 pages		CD, Number of CD(s)		3. Return Receipt Postcard	
Certified Copy of Priorit	у	Landscape Table on	CD		
Reply to Missing Parts/ Incomplete Application	Re	marks	-		
Reply to Missing 37 CFR 1.52 or 1					
	SIGNATURE O	F APPLICANT, ATTOR	RNEY, OR	AGENT	
Firm Name MORRIS	ON & FOERSTE	R LLP (Customer No	. 20872)		
Signature	ichael	Pulu			
Printed name Michael I	R. Ward				
Date May 5, 2	005		Reg. No.	38,651	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV731514203US,
in an envelope addressed to: Commissioner for Patents, P.O. Box 1/450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 5, 2005

(Laura Tsang)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 731514203 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Qated: May 5, 2005

Signature:

(Laura reage)

Patent Docket No. 416272003700 B01-074

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marc K. HELLERSTEIN

Serial No.: 10/664,513

Filing Date: September 16, 2003

For: BIOCHEMICAL METHODS FOR

MEASURING METABOLIC FITNESS OF TISSUES OR WHOLE ORGANISMS Examiner: Not Yet Assigned

Group Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:
With the application; accordingly, no fee or separate requirements are required.
Before the mailing of a first Office Action after the filing of a Request for Continued
Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
(e)(1) has been provided.

Within three months of the application filing date or before mailing of a first Office					
Action	n on the merits; accordingly, no fee or separate requirements are required.				
Howe	ver, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.				
After	receipt of a first Office Action on the merits but before mailing of a final Office Action				
or Notice of Allowance.					
A fee is required. A check in the amount of is enclosed.					
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to				
	this submission in duplicate.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is				
	believed to be due.				
After	mailing of a final Office Action or Notice of Allowance, but before payment of the				
issue fee.					
A Certification under 37 C.F.R. § 1.97(e) is provided above and a check					
	amount of is enclosed.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				
	form (PTO/SB/17 is attached to this submission in duplicate.)				
	Action Howe After is or Not				

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 416272003700.

Dated: May 5, 2005

Respectfully submitted,

Michael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

(415) 268-6237



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known			
Application Number	10/664,513			
Filing Date	September 16, 2003			
First Named Inventor	Marc K. HELLERSTEIN			
Art Unit	1645			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	416272003700			

		U	.S. PATENT DOCUME	NTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-4,332,784	06-01-1982	Smith et al.	
	2.	US-5,439,803	08-08-1995	Ross et al.	
	3.	US-6,653,076	11-25-2003	Franza, Jr. et al.	
	4.	US-2003/0148533	08-07-2003	Malloy et al.	
	5.	US-2003/0180710	09-25-2003	Lee et al.	
	6.	US-2003/0180800	09-25-2003	Lee et al.	
	7.	US-2003/0228259-A1	12-11-2003	Hellerstein	
	8.	US-2004/0091943	05-13-2004	Schneider	
	9.	US-2004/0115131-A1	06-17-2004	Hellerstein	
	10.	US-2004/0152994	08-05-2004	Meier-Augenstein	
	11.	US-2004/0253647	12-16-2004	Mathews et al.	
	12.	US-2005/0019251-A1	01-27-2005	Hellerstein	
	13.	US-2005/0053992-A1	03-10-2005	Hellerstein	
	14.	US-10/519,121	FD 09-15-2003	Hellerstein	
	15.	US-10/523,250	FD 01-26-2005	Hellerstein	
	16.	US-10/526,860	FD 09-04-2003	Hellerstein	
	17.	US-10/872,280	FD 06-17-2004	Hellerstein	,
	18.	US-10/963,967	FD 10-12-2004	Hellerstein	
	19.	US-10/997,323	FD 11-23-2004	Hellerstein	
	20.	US-11/064,197	FD 02-22-2005	Hellerstein	
	21.	US-11/078,083	FD 03-11-2005	Hellerstein	
	22.	US-11/094,387	FD 03-29-2005	Hellerstein	

		FOREIG	GN PATENT DOC	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
	23.	WO-90/11371	10-04-1990	Anticancer, Inc.		
	24.	WO-93/25705	12-23-1993	Barranco		
	25.	WO-03/061479-A1	07/31/2003	Hellerstein		
	26.	WO-03/068919-A2	08/21/2003	Hellerstein		
	27.	WO-03/087314-A2	10/23/2003	Hellerstein		
	28.	WO-04/003493-A2	01/08/2004	Hellerstein		
	29.	WO-04/011426-A2	02/05/2004	Hellerstein		
	30.	WO-04/021863-A2	03/18/2004	Hellerstein		
	31.	WO-04/024941-A2	03/25/2004	Hellerstein		
	32.	WO-04/025270-A2	03/25/2004	Hellerstein		

Examiner	Date
Signature	Considered

Sut	estitute for form 1449/PTO				Complete if Known
	(Use as many sheets as necessary)		Application Number	10/664,513	
II.		SCLOSURE	Filing Date	September 16, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	416272003700

3	3.	WO-04/042360-A2	05/21/2004	Hellerstein	
3	4.	WO-05/009597-A2	02/03/2005	Hellerstein	
3	5.	WO-05/015155-A2	02/17/2005	Hellerstein	
[3	6.	WO-05/033652-A2	04/14/2005	Hellerstein	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	37.	International Search Report mailed on January 19, 2005, for PCT application no. PCT/US03/29361 filed on September 15, 2003, 4 pages	
	38.	International Search Report mailed July 8, 2004, for PCT patent application no. PCT/US03/27623 filed on September 4, 2003, 4 pages	
	39.	International Search Report mailed on March 25, 2005, for PCT applicattion no. PCT/US04/39722 filed on November 24, 2004, 3 pages	
	40.	International Search Report mailed on August 20, 2004, for PCT application no. PCT/US03/10554 filed on April 4, 2003, 4 pages	
	41.	International Search Report mailed on July 9, 2004, for PCT application no. PCT/US03/35107 filed on November 4, 2003, 2 pages	
	42.	International Search Report mailed on June 29, 2004, for PCT application no. PCT/US03/04183 filed on February 12, 2003, 4 pages	
	43.	International Search Report mailed on April 4, 2005, for PCT application no. PCT//US04/21063 filed on June 29, 2004, 2 pages	
	44.	"New Diagnostic Technique Could Help Treat AIDS," Agence France-Presse, Dow Jones News/Retrieval, Feb. 17, 1998, pp. 1-2.	
	45.	ADAMI, H.O. et al. (1995) "The Aetiology and Pathogenesis of Human Breast Cancer" <i>Mutation Research</i> 333: 29-35	
	46.	ANDERSON, R.W. et al. (1998) "Direct HIV Cytopathicity Cannot Account for CD4 Decline in AIDS in the Presence of Homeostasis: A Worst-Case Dynamic Analysis" <i>J. AIDS and Human Retrovirology</i> 17:245-252	
	47.	ASHER, E. et al. (1995) "Evaluation of Cell Death in EBV-Transformed Lymphocytes Using Agarose Gel Electrophoresis, Light Microscopy and Electron Microscopy" <i>Leukemia and Lymphoma</i> 19:107-119	

Examiner	Date	te
Signature	Con	nsidered

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/664,513	
IN.	IFORMATION	1 DI	SCLOSURE	Filing Date	September 16, 2003	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
	•			Art Unit	1645	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 3 of 8		Attorney Docket Number	416272003700		

	. '
, ,	
Atherosclerosis to National Cholesterol Education Program-	
Recommended Low-Density-Lipoprotein Cholesterol Goals with	
Atorvastatin, Fluvastatin, Lovastatin and Simvastatin" J. Am. Coll.	
Cardiol. 32: 665-672	
BUCY, R.P. et al. (1998) "Analysis of Lymph Node Biopsies in HIV	
that are not Immediately Restored by Antiviral or Immune-Based	
CRAIN, P.F.(1990) "Preparation and Enzymatic Hydrolysis of DNA and	
	Atorvastatin, Fluvastatin, Lovastatin and Simvastatin" J. Am. Coll. Cardiol. 32: 665-672 BUCY, R.P. et al. (1998) "Analysis of Lymph Node Biopsies in HIV Infected Patients Before and After HAART" Abstract, 5th Conference on Retroviruses and Opportunistic Infections, Session 66 519:177 CALDWELL, K.A. et al. (1993) "Quantification of Peptide Isotopomer Abundances and Determination of Protein (sic) Turnover Rates by Using Mass Isotopomer Distribution Analysis" Abstract, 41st Annual Amer. Society Mass Spectrometry on Mass Spectrometry, p. 331a. CASSELLA, C.R. et al. (1997) "Mechanisms of Lymphocyte Killing by HIV" Current Opinion in Hematology 4:24-31 CESAR, D. et al. (1998) "Direct Measurement of CD4+ and CD8+ T Cell Proliferation Rates in Vivo in AIDS Patients Using a Stable Isotope-Mass Spectrometric Technique" Abstract, 5th Conference on Retroviruses and Opportunistic Infections, Chicago Illinois COHEN, A. et al. (1983) "Purine and Pyrimidine Metabolism in Human T Lymhocytes," J. Biol. Chem. 258(20):12334-12340 COHEN, J. (1998) "Failure Isn't What It Used to BeBut Neither is Success" Science 279:1133-1134 CONNERS, M. et al. (1997) "HIV Infection Induces Changes in CD4+ T-Cell Phenotype and Depletions Within the CD4+ T-Cell Repertoire that are not Immediately Restored by Antiviral or Immune-Based Therapies" Nature Medicine 3(5):533-540

Examiner	Date	
Signature	Considered	

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/664,513	
11	NFORMATION	I DIS	SCLOSURE	Filing Date	September 16, 2003	
l s	TATEMENT E	BY A	PPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	heet 4 of 8		Attorney Docket Number	416272003700		

		RNA for Mass Spectrometry," Meth. Enz. 193:782-790	
	62.	DEEKS, S. et al. (1998) "Viral Load and CD4+ T Cell Changes in	
		Patients Failing Potent Protease Inhibitor Therapy" Abstract, 5th	
		Conference on Retroviruses and Opportunistic Infections, Session 53,	
		419:158	
	63.	DIMITROV, D.S. et al. (1995) Scientific Correspondence, Nature	
		375:194-195	
	64.	GOROCHOV, G. et al. (1998) "Perturbation of CD4+ and CD8+ T-Cell	
1	ļ	Repertoires During Progression to AIDS and Regulation of the CD4+	
	_	Repertoire During Antiviral Therapy," Nature Medicine 4(2):215-221	
	65.	GOZ, Barry (1978) "The Effects of Incorporation of 5-Halogenated	
		Deoxyuridines into DNA of Eukaryotic Cells" Macological Reviews 29,	
		(4): 249-272	
	66.	GRATZNER, H.G. (1982) "Monoclonal Antibody to 5-Broma-and 5-	
1		Iododeoxyuridine: A New Reagent for Detection of DNA Replication"	
		Science 218:474-475	
	67.	HELLERSTEIN, M.K. et al. (1997) "T Cell Turnover in HIV-1 Disease,"	
		Immunity 7:583-589 (Nov. 1997).	
	68.	HO, D.D. et al. (1995) "Rapid Turnover of Plasma Virions and CD4	
		Lymphocytes in HIV-1 Infection," Nature 373:123-126	
	[69.	HSIEH, Elaine A. et al. (2004) "Dynamics of Keratinocytes in Vivo	
		Using 2H2O Labeling: A Sensitive Marker of Epidermal Proliferation	
		State," J Invest Dermatol, 123: 530-536	
	70.	JAMES, J.S. (1998) "Clinical Implications of Virological Failure:	
		Interview with Steven Deeks, M.D., San Francisco General Hospital,"	
		AIDS Treatment News, 289:6-7	
	71.	LEWANCZUK, Richard Z. et al. (2004) "Comparison of the [13 C]	
		Glucose Breath Test to the Hyperinsulinemic-Euglycemic Clamp When	
		Determining Insulin Resistance" Diabetes Care 27(2):441-447	
	72.	LIPKIN, M. (1987) "Proliferation and Differentiation of Normal and	
	ŀ	Diseased Gastrointestinal Cells" In Physiology of the Gastrointestinal	
		Tract, L.R. Johnson ed., Raven Press, New York, pp. 255-284	
	73.	LIPKIN, Martin et al. (1963) "Cell Proliferation Kinetics in the	
		Gastrointestinal Tract of Man. I. Cell Renewal in Colon and Rectum"	
L		Journal of Clinical Investigations 42(6):767-776	
	74.	MAENTAUSTA, O. et al. (1979) "Radioimmunoassay of Conjugated	
		Cholic Acid, Chenodeoxycholic Acid, and Deoxycholic Acid from	
		Human Serum, with Use of 125I-Labeled Ligands" Clin. Chem. 25(2):	
		264-268	L

Examiner	Date .
Signature	12
Signature	Considered
5 10 10 100	

Sut	stitute for form 1449/PTO			Complete if Known		
	,			Application Number	10/664,513	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	September 16, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
		•		Art Unit	1645	
	(Use as many she	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	neet 5 of 8		Attorney Docket Number	416272003700		

75.	MARGOLICK, J.B. et al. (1995) "Failure of T-cell Homeostasis Preceding AIDS in HIV-1 Infection," <i>Nature Medicine</i> , 1(7):674-680	
76.	MCCLOSKEY, J.A. (1990) "Electronionization Mass Spectra of Trimethylsilyl Derivatives of Nucleosides," <i>Meth. Enz.</i> 193:825-841	
77.	MCCUNE, J.M. (1997) "Thymic Function in HIV-1 Disease," Seminars in Immunology 9:397-404	
78.	MCLEAN, A.R. et al. (1995) "In Vivo Estimates of Division and Death Rates of Human T Lymphocytes," <i>Proc. Natl. Acad. Sci USA</i> 92:3707-3711	
79.	MEIER, P.R. et al. (March 1981) "Rates of Protein Synthesis and Turnover in Fetal Life," Am J Physiol., 240(3):E320-E324	
80.	MELLORS, J.W. et al. (1995) "Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion," <i>Ann. Intern. Med.</i> 122:573-579	144
81.	MELLORS, J.W. et al. (1996) "Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma," <i>Science</i> , 272:1167-70	
82.	MESSMER, Bradley T. et al. (Feb. 10, 2005) "In Vivo Measurements Document the Dynamic Cellular Kinetics of Chronic Lymphocytic Leukemia B Cells," J. Clin. Invest. doi:10.1172/JCl200523409	
83.	MICHIE, C.A. et al. (1992) "Lifespan of Human Lymphocyte Subsets Defined by CD45 Isoforms," <i>Nature</i> 360:264-265	
84.	MORRIS, Rebecca J. et al. (1997) "Evidence that a Slowly Cyling Subpopulation of Adult Murine Epidermal Cells Retains Carcinogen" Cancer Research 46: 3061-3066	
85.	MORRIS, Rebecca J. et al. (1997) "Evidence that Cutaneous Carcinogen-initiated Epithelial Cells from Mice are Quiescent Rather than Actively Cyling" Cancer Research 57:3436-3443	
86.	MOSIER, D.E. (1995) "CD4.sup.+ Cell Turnover," Nature 375:193-194	
87.	MURALI-KRISHNA, K. et al. (1998) "Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection," <i>Immunity</i> 8:177-187	
88.	NEESE, R. A. et al. (Nov. 2002) "Measurement in vivo of Proliferation Rates of Slow Turnover Cells by 2H2O Labeling of the Deoxyribose Moiety of DNA," PNAS, 99(24): 15345-15350	
89.	OYAIZU, N. et al. (1995) "Role of Apoptosis in HIV Disease Pathogenesis," <i>J. of Clinical Immunology</i> 15(5):217-231	
90.	PALMER, L.D. et al. (1997) "Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+ T Cells from HIV-discordant Monozygotic Twins," <i>J. Experimental</i>	

Examiner	Date
Signature	Considered

Sut	estitute for form 1449/PTO			Complete if Known		
				Application Number	10/664,513	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	September 16, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	8	Attorney Docket Number	416272003700	

i .		Modicine 185(7):1381 1386	
	91.	Medicine 185(7):1381-1386	
	J ₉₁ .	PAPAGEORGOPOULOS, C. et al.(1993) "Toward the Measurement of	
1	1	Protein Synthesis by Mass Isotopomer Distribution Analysis	
	1	(MIDA):Resolution of Isotopomers in a [d.sub.3]-Leucine Enriched	
		Synthetic Oligopeptide Using Electrospray/Quadrupole Mass	
l		Spectrometry (ESI/MS)," Abstract, Federation of American Societies	
	-	for Experimental Biology 1022:A177	
	92.	PARK, S. S., et al. (1997) "Measurement of Small Intestinal Cell	
		Turnover with [6,6, 2H2] Glucose," Berkeley Scientific, Abstract	
	-	1(2):41-43	
	93.	PATTON, G.M. et al. (July 1979) "Measurements of Fatty Acid	
		Synthesis by Incorporation of Deuterium from Deuterated Water,"	
		Biochemistry, 18(14):3186-3188	
	94.	PERELSON, A.S. et al.(1996) "HIV-1 Dynamics in Vivo: Virion	
		Clearance Rate, Infected Cell Life-Span, and Viral Generation Time,"	
		Science 271:1582-1586	<u> </u>
	95.	PERELSON, A.S. et al.(1997) "Decay Characteristics of HIV-1-	
		Infected Compartments During Combination Therapy," Nature	
		387:188-191	
1	96.	POZHARISSKI, K.M. et al. (1980) "Study of Kinetics of Epithelial Cell	
		Populations in Normal Tissues of the Rat's Intestines and in	
	ļ	Carcinogenesis." Exp. Path., Bd. 18:387-406	
	97.	REICHARD, P. (1978) "From Deoxynucleotides to DNA Synthesis,"	
		Federation Proceedings 37(1):9-14	
1	98.	REICHARD, P. (1988) "Interactions Between Deoxyribonucleotide and	
		DNA Synthesis," Ann. Rev. Biochem. 57:349-374	
	99.	ROCHA, B. et al. (1990) "Accumulation of Bromodeoxyuridine-	
		Labelled Cells in Central and Peripheral Lymphoid Organs: Minimal	
		Estimates of Production and Turnover Rates of Mature Lymphocytes"	
		Eur. J. Immunol. 20:1697-1708	
	100.	RODA, Aldo et al. (1980) "Results with Six 'Kit' Radioimmunoassays	
		for Primary Bile Acids in Human Serum Intercompared" Clin. Chem.	
		26(12): 1677-1682	
	101.	ROEDERER, M. (July 1995) "T-Dell Dynamics of Immunodeficiency,"	
L		Nature Medicine 1(7):621-622	
	102.	SAWADA, S. et al. (1995) "Comparison of Autoradiography, Liquid	
		Scintillation Counting and Immunoenzymatic Staining of 5-bromo-2'-	
		deoxyuridine for Measurement of Unscheduled DNA Synthesis and	
		Replicative DNA Synthesis in Rat Liver," Mutation Research 344:109-	

Examiner	Date
Signature	Considered

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/664,513	
IN	IFORMATION	I DI	SCLOSURE	Filing Date	September 16, 2003	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Marc K. HELLERSTEIN	
(Use as many sheets as necessary)				Art Unit	1645	
				Examiner Name	Not Yet Assigned	
Sheet	7	of	8	Attorney Docket Number	416272003700	

	116	-
	SCALISE, K. (Feb. 11-17, 1998) "Tracking T-Cells in AIDS Patients: A Safe Reliable Method of Measuring Human Cell Generation Rates," <i>Berkeleyan,</i> p. 3.	
104.	SHIGENAGA, M.K. et al. (1994) "Assays of Oxidative DNA Damage Biomarkers 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine in Nuclear DNA and Biological Fluids by High-Performance Liquid Chromatography with Electrochemical Detection," <i>Methods in Enzymology</i> 234:16-33	
105.	· · · · · · · · · · · · · · · · · · ·	
106.	SPRENT, J. et al. (1995) "CD4+ Cell Turnover," Nature 375:194	
107.	SUNTER, J.P. et al. (1978) "Cell Population Kinetics in the Epithelium of the Colon of the Male Rat." Virchows Archiv. B Cell Path. 26: 275-287	
	TINT, G.S. et al. (1974) "Transformation of $5a$ -cholest-7-en-3 β -ol to Cholesterol and Cholestanol in Cerebrotendinous Xanthomatosis" Journal of Lipid Research 15: 256-262	
109.	TRABER, P.G. et al. (1991) "Isolation of Intestinal Epithelial Cells for the Study of Differential Gene Expression Along the Crypt-Villus Axis," <i>Am. J. Physiol.</i> 260:G895-G903	
110.	WADKE, M. et al. (July 1973) "Fatty Acid Synthesis by Liver Perfused with Deuterated and Tritiated Water," Biochemistry., 12(14):2619-2624	
111.	WAIN-HOBSON, S. (1995) "Virological Mayhem," Nature 373:102	
112.	WALDEMAN, F.M. et al. (1991) "A Comparison Between Bromodeoxyuridine and 3 H Thymidine Labeling in Human Breast Tumors," <i>Modern Path.</i> 4(6):718-722	
113.	WEI, X et al. (1995) "Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection," <i>Nature</i> 373:117-122	
114.	WOLFE, R. (1990) "Isotopic Measurement of Glucose and Lactate Kinetics," <i>Ann. Med.</i> 22:163-170	
115.	WOLTHERS et al. (1998) "Rapid CD4+ T-Cell Turnover in HIV-1 Infection: a Paradigm Revisited," <i>Immunol. Today</i> 19(1):44-48	
116.	WOLTHERS, K.C. et al. (1996) "T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover," <i>Science</i> 274:1543-1547	
117.	WOOD, H.G. et al. (1963) "Estimation of Pathways of Carbohydrate	

Examiner	Date	
Signature	Considered	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/664,513	
IN.	NFORMATION	1 DI	SCLOSURE	Filing Date	September 16, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Marc K. HELLERSTEIN	
				Art Unit	1645	
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	8	of	8	Attorney Docket Number	416272003700	

	Metabolism," Biochemische Zeitschrift 338:809-847	
11	8. ZHANG, Z-Q. et al. (Feb. 1998) "Kinetics of CD4+ T Cell Repopulation of Lymphoid Tissues after Treatment of HIV-1 Infection," <i>Proc. Natl. Acad. Sci. USA</i> 95:1154-1159	
11	9. ZILVERSMIT, D.B. et al. (1943) "On the Calculation of `Turnover Time` and `Turnover Rate` from Experiments Involving the Use of Labeling Agents," <i>J. of General Physiology</i> 26(3):325-331	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.